Is Globus Medical, Inc. overvalued or undervalued?

As of 16 June 2025, the valuation grade for Globus Medical, Inc. has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a P/E ratio of 36, an EV to EBITDA of 13.54, and a PEG ratio of 0.54, indicating a more favorable valuation relative to its growth prospects.
In comparison to its peers, Globus Medical's P/E ratio of 36 is lower than that of Inspire Medical Systems, Inc., which has a P/E of 56.43, suggesting that Globus may be a more attractive investment at its current valuation. However, it is worth noting that Natera, Inc. and Masimo Corp. show extreme valuations, with P/E ratios of -120.56 and 378.77, respectively, highlighting the variability in the sector. Despite recent underperformance compared to the S&P 500, with a year-to-date return of -30.11% versus the index's 2.44%, the company's fair valuation suggests potential for recovery as market conditions improve.